About the DAMNIT-V Screen
What DAMNIT-V Measures
DAMNIT-V is a functional screening system that measures a physiological response of magnetic repulsion while the patient is exposed to a defined test signal. Magnetic repulsion causes cessation of biological signalling and disrupts biochemical pathways.
The system does not directly detect a pathogen, hormone, toxin, gene or disease. Instead, it asks a different question:
Does the patient produce a measurable physiological response when exposed to this particular test signal?
The response is recorded as transient RAC-type events. The number and pattern of these events provide a quantitative measure of physiological reactivity during the defined exposure period.
The Test Signal
Each DAMNIT-V test uses a predefined signal representing the biological target being investigated.
For example, a screening library may contain signals associated with a hormone, receptor, protein, pathogen, toxin or physiological pathway.
The signal identifies what is being tested. The RAC response measures how the patient responds to that signal.
How a Result Is Produced
Defined test signal → Patient exposure → Physiological response → RAC events detected → Response quantified → Clinical interpretation domains aligned with the DAMNIT-V framework. These responses are interpreted in context, alongside history, examination, and conventional diagnostics.
Top image: equal magnetic measurement of a wall ( 1st signal is a heartbeat – it measured my heartbeat) ; Middle image is a magnetic measurement of my heartbeat; Bottom image is RAC measurement when I was exposed to Coffee – two very distinct RAC signals.
The RAC signal is a configuration of peaks and valleys with at least 3 peaks, and there is a Delta T measurement.
Biological Correlation
In the cranial cruciate ligament work, screening responses associated with HPG/LHR signalling were investigated alongside independent biological and clinical findings, including:
- surgically confirmed CCr disease;
- histopathology immunofluorescent assessment of LHR expression in affected tissue; and
- recorded HPG-axis screening responses.
This provides correlation evidence between the functional screening observations and independently observed tissue biology. It does not, by itself, establish diagnostic sensitivity, specificity or causation.
Longitudinal Clinical Evidence
Then retain your 2014–2025 dataset, but make it much shorter.
Something like:
Because the study was observational, uncontrolled and a downward trend existed before intervention, these findings demonstrate a temporal association rather than proof of causation.
They are not validated diagnostic thresholds.
A 12-year single-practice observational dataset recorded 80 CCr disease cases. Following introduction of the targeted HPG-axis protocol in 2022, recorded annual cases were 7, 5, 4 and 1 from 2022–2025.
Mean annual recorded cases were 7.88 during 2014–2021 and 4.25 during 2022–2025.
Biological Focus: HPG Axis and LHR
Existing literature suggests possible links between:
- Post-desexing endocrine shifts
- Gonadotrophin signalling
- Connective tissue integrity
For this reason, hypothalamic–pituitary–gonadal (HPG) axis signalling, and specifically luteinising hormone receptor (LHR) signalling, was selected as a biologically plausible focus for investigation. The diagrams below illustrate the normal gonadal feedback relationship and the altered endocrine environment following gonadectomy. Images below show the hormones in an entire patient and a desexed patient.
Correlation Phase
During the correlation phase, screening outputs indicating HPG-axis reactivity were compared with:
- Surgically confirmed CCr rupture
- Immunofluorescent detection of LHR expression in cruciate tissue
This was a correlation study, not a diagnostic validation trial.
The objective was to assess alignment between repeatable functional response patterns and tissue-level biological markers.s whether repeatable functional response patterns aligned with biological markers present in diseased tissue.
H&E stains of normal CCr and Ruptured CCr as reference
H&E Stain of ruptured CCR in study
Immunofluorescent LHR stain in ruptured CCr : Score 6/6 based on Kiefel and Kutzler 2020
HPG hormone screen of patient in CCr study
LHR study of the stifle in CCr patient included in the study
Tissue-Level Controls
Samples were obtained only from clinically indicated surgical cases.
A histologically normal cruciate control group was not included because:
- Invasive sampling of healthy cruciate ligaments is not ethically justified
- There is no clinical indication for routine sampling of intact ligaments
Accordingly, the study design was case-referenced rather than case–control at tissue level.
This supports the discussion of correlation but does not allow inference about marker absence in normal tissue.
Longitudinal Observational Cohort (2014–2025)
Design
- Single-practice longitudinal observational dataset
- 12 calendar years of clinical observations (2014–2025)
- Annual recorded CCr disease case counts Desexed dogs managed within routine veterinary practice
- Pre-HPG-intervention period: 2014–2021
- Targeted HPG-intervention period: 2022–2025
Intervention
- The targeted HPG-axis protocol introduced in 2022 incorporated:
- Functional screening for HPG-axis-associated reactivity;
- Post-operative music for HPG – every patient listened to the music for 3 weeks
- Targeted Acupuncture and Music intervention in reactive cases that did not respond to music alone ;
- Serial reassessment weekly for three weeks post-desexing.
Example of the HPG music contents:
Observed Findings
Across the 2014–2025 dataset, 80 recorded CCr disease cases were represented.
Before introduction of the targeted HPG intervention (2014–2021), 63 cases were recorded, with a mean of 7.88 cases per year.
During the HPG intervention period (2022–2025), 17 cases were recorded, with a mean of 4.25 cases per year — 46.0% lower than the pre-intervention mean annual case count.
Following introduction of the HPG intervention, annual recorded CCr cases declined sequentially:
2022: 7 → 2023: 5 → 2024: 4 → 2025: 1
This represents an 85.7% reduction in annual recorded case count from 2022 to 2025.
Exploratory linear regression across the four intervention years demonstrated a strong negative temporal trend (slope −1.90 cases/year; R² = 0.963; p = 0.0188).
Importantly, a downward temporal trend was already present before 2022. The post-intervention findings therefore demonstrate a temporal association, not proof that the HPG intervention caused the observed reduction.
Scientific Clarification
This dataset:
- Is observational
- Is not randomised
- Was not blinded
- Does not establish causation
- Does not define sensitivity or specificity
- Does not establish predictive validity
It demonstrates longitudinal consistency and feasibility in a real-world clinical setting. The available historical dataset does not provide a validated annual population-at-risk denominator; therefore, the longitudinal outcome is reported as annual CCr disease occurrence/case count rather than incidence
Further controlled, prospective research is required to determine:
- Mechanistic pathways
- Effect magnitude
- Reproducibility
- Diagnostic performance characteristics
- What This Evidence Supports
- Long-term integration feasibility
- Internal consistency of application
- Correlation between screening-guided management and observed practice-level outcomes
What It Does Not Support
Replacement of structural diagnostics
Population-level risk reduction claims
Causal inference
Predictive disease prevention claims
y over time, not proof of causation, prediction, or disease prevention.
Why DAMNIT-V Screen Exists
DAMNIT-V Screen exists because it demonstrated consistent clinical utility within clearly defined scientific boundaries.
It was built in practice, refined through daily use, and designed to support the way experienced veterinarians already think:
Start broadly, narrow carefully, and investigate appropriately.
Explore further clinical uses of the DAMNIT-V Screen, or arrange an in-clinic demonstration via the Contact page.